Friday, April 25, 2014

Aurinia to begin lupus nephritis trial in Q2

Aurinia to begin lupus nephritis trial in Q2

April 15, 2014 by · Leave a Comment 

Tweet Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient in the next few weeks in a Phase 2b clinical trial with its voclosporin immunosuppressant in combination with CellCept®, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “We are now well […]

M Partners starts Aurinia at buy

M Partners starts Aurinia at buy

April 10, 2014 by · Leave a Comment 

Tweet M Partners has initiated coverage of Aurinia Pharmaceuticals (TSX-V:AUP) with a “buy” rating and target price of $6.15. The stock closed at $3.20 on Wednesday. Analyst Daniel Pearlstein writes that the company’s voclosporin drug candidate, which is scheduled to begin a Phase 2b study for the treatment of lupus nephritis, has a wealth of […]

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia readies Phase 2b trial in lupus nephritis

November 19, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating lupus nephritis (LN), the most severe form of lupus. “The core of our management team executed the Aspreva Lupus Management Study, which […]

Aurinia names Stephen Zaruby as president & CEO

Aurinia names Stephen Zaruby as president & CEO

November 6, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) has appointed accomplished biotech and pharma executive, Stephen Zaruby, as president and CEO. Mr. Zaruby has a strong track record of strategic operations, sales and marketing, research and development, and general management success in the global biotechnology and pharmaceutical industries. Previously, he was president of Seattle-based ZymoGenetics, which was acquired by Bristol-Myers […]

Isotechnika officially changes name to Aurinia Pharma

Isotechnika officially changes name to Aurinia Pharma

October 22, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX-V:ISA) has officially changed its name to Aurinia Pharmaceuticals and its common shares will be posted for trading on a 50:1 consolidated basis on the TSX Venture Exchange at the opening tomorrow under the trading symbol, AUP. The consolidation will result in 12,373,589 shares outstanding. “In many respects, the new Aurinia just […]

Aurinia makes post-merger management changes

Aurinia makes post-merger management changes

October 22, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:ISA), formerly Isotechnika Pharma, unveiled a post-merger strategic restructuring, including senior management changes, designed to further position the company to successfully bring voclosporin to market as a therapy for lupus nephritis. Dr. Richard Glickman has been appointed executive chairman and acting CEO, succeeding Dr. Robert Foster, who moves to the post of […]

Isotechnika, Aurinia complete merger, financing

Isotechnika, Aurinia complete merger, financing

September 23, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals have completed their merger and will operate under the name, Aurinia Pharmaceuticals. The transaction was approved by shareholders on Aug. 15. In connection with the merger, the company has completed, subject to regulatory approval, a private placement of 133,333,332 units, consisting of one common share and one half […]

Isotechnika sets meeting to vote on merger for Aug. 15

Isotechnika sets meeting to vote on merger for Aug. 15

July 25, 2013 by · Leave a Comment 

Tweet A meeting of Isotechnika Pharma (TSX:ISA) shareholders to consider a proposed merger with closely held Aurinia Pharmaceuticals will be held on Aug. 15. The boards of Isotechnika and Aurinia firmly support the proposed merger, which is designed to create a premier clinical stage pharmaceutical company focused on the global nephrology market. The merger is […]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including […]

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

Takeda deal in lupus highlights Isotechnika-Aurinia merger potential

February 28, 2013 by · Leave a Comment 

Tweet A $255-million development partnership between Takeda Pharmaceutical and Resolve Therapeutics to develop compounds for the treatment of lupus and other autoimmune diseases highlights the potential of a merger between Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals to develop Isotechnika’s voclosporin drug for lupus nephritis. Resolve’s lead compound, RSLV-132, will begin clinical development later this year. […]

Next Page »

Google+